Skip to main content
NCBI home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;11(4):341–352. doi: 10.1111/j.1527-3458.2005.tb00052.x

ATC0175: An Orally Active Melanin‐Concentrating Hormone Receptor 1 Antagonist for the Potential Treatment of Depression and Anxiety

Shigeyuki Chaki 1,✉, Jun‐ichi Yamaguchi 1, Hisaharu Yamada 1, William Thomsen 2, Thuy‐Anh Tran 2, Graeme Semple 2, Yoshinori Sekiguchi 1
PMCID: PMC6741758  PMID: 16614734

ABSTRACT

Melanin‐concentrating hormone (MCH) has been implicated in a variety of physiological events. Recent studies clearly suggest that MCH plays an important role in the regulation of stress and emotion. To date, two receptor subtypes of MCH (MCH1R and MCH2R) have been identified. MCH1R has been suggested to mediate most of the physiological functions of MCH. Recently, we synthesized an orally active, nonpeptidic antagonist of MCH1R, N‐(cis‐4‐([4‐(dimethylamino)quinazolin‐2‐yl]amino)cyclohexyl)‐3,4‐difluorobenzamide hydrochloride (ATC0175). This compound is a potent antagonist with a high affinity for MCH1R and additional affinities for 5‐HT1A and 5‐HT2B receptors. The receptor binding and the functional assay (MCH‐induced increase in [Ca2+]i) indicated that ATC0175 is a noncompetitive antagonist at MCH1Rs. ATC0175 exhibited anxiolytic effects in numerous animal models of anxiety including the elevated plus‐maze test, social interaction test, stress‐induced hyperthermia and maternal separation‐induced vocalization. Like with other stress‐related peptide receptor antagonists, such as antagonists of corticotropin‐releasing factor or vasopressin V1b receptor antagonists, anxiolytic effects of ATC0175 were more pronounced in models containing a stress component. ATC0175 also exhibited antidepressant effects in the forced swimming test. ATC0175 increased swimming performance without altering climbing behavior, as observed with selective serotonin reuptake inhibitors. ATC0175 has adequate ADME profile (reasonable oral bioavailability and brain penetration) and potent oral activity in animal models. In contrast, ATC0175 did not affect spontaneous locomotor activity, hexobarbital‐induced sleeping time and did not impair rotarod performance. Thus, ATC0175 may be devoid of unwanted central nervous system side effects, which are sometimes observed with current medications. In addition, ATC0175 was well tolerated in rat repeated toxicity study, and had no genotoxic liability. Therefore, ATC0175 has the potential to be effective in the treatment of patients with depression and/or anxiety disorders.

Keywords: Anxiety, ATC0175, Depression, MCH, MCH1R, MCH2R, Melanin‐concentrating hormone

Full Text

The Full Text of this article is available as a PDF (120.4 KB).

References

  • 1. Adamantidis A, Thomas E, Foidart A, et al. Disrupting the melanin‐concentrating hormone receptor 1 in mice leads to cognitive deficits and alterations of NMDA receptor function. Eur J Neurosci 2005;21:2837–2844. [DOI] [PubMed] [Google Scholar]
  • 2. . American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Washington : American Psychiatric Press, 1994. [Google Scholar]
  • 3. Bittencourt JC, Presse F, Arias C, et al. The melanin‐concentrating hormone system of the rat brain: An immuno‐ and hybridization histochemical characterization. J Comp Neurol 1992;319:218–245. [DOI] [PubMed] [Google Scholar]
  • 4. Borowsky B, Durkin MM, Ogozalek K, et al. Antidepressant, anxiolytic and anorectic effects of a melanin‐concentrating hormone‐1 receptor antagonist. Nat Med 2002;8:825–830. [DOI] [PubMed] [Google Scholar]
  • 5. Borsini F, Podhorna J, Marazziti D. Do animal models of anxiety predict anxiolytic‐like effects of antidepressants Psychopharmacology (Berlin) 2002;163:121–141. [DOI] [PubMed] [Google Scholar]
  • 6. Chaki S, Funakoshi T, Hirota‐Okuno S, et al. Anxiolytic‐ and antidepressant‐like profile of ATC0065 and ATC0175: Nonpeptidic and orally active melanin‐concentrating hormone receptor 1 antagonists. J Pharmacol Exp Ther 2005;313:831–839. [DOI] [PubMed] [Google Scholar]
  • 7. Chen Y, Hu C, Hsu CK, et al. Targeted disruption of the melanin‐concentrating hormone receptor‐1 results in hyperphagia and resistance to diet‐induced obesity. Endocrinology 2002;143:2469–2477. [DOI] [PubMed] [Google Scholar]
  • 8. Chiocchio SR, Gallardo MG, Louzan P, Gutnisky V, Tramezzani JH. Melanin‐concentrating hormone stimulates the release of luteinizing hormone‐releasing hormone and gonadotropins in the female rat acting at both median eminence and pituitary levels. Biol Reprod 2001;64:1466–1472. [DOI] [PubMed] [Google Scholar]
  • 9. Collins CA, Kym PR. Prospects for obesity treatment: MCH receptor antagonists. Curr Opin Investig Drugs 2003;4:386–394. [PubMed] [Google Scholar]
  • 10. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: Recent developments and future needs. Trends Pharmacol Sci 2002;23:238–245. [DOI] [PubMed] [Google Scholar]
  • 11. David DJ, Saxe M, Craig D, et al. Antidepressant‐like effect of SNAP94847, a melanin concentrating hormone‐1 receptor antagonist. Abstr 34thSoc Neurosci Meeting 2004;#356.1. [Google Scholar]
  • 12. Georgescu D, Sears RM, Hommel JD, et al. The hypothalamic neuropeptide melanin‐concentrating hormone acts in the nucleus accumbens to modulate feeding behavior and forced‐swim performance. J Neurosci 2005;25:2933–2940. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Griebel G, Simiand J, Stemmelin J, Gal CS, Steinberg R. The vasopressin V1b receptor as a therapeutic target in stress‐related disorders. Curr Drug Targets CNS Neurol Disord 2003;2:191–200. [DOI] [PubMed] [Google Scholar]
  • 14. Hervieu GJ, Cluderay JE, Harrison D, et al. The distribution of the mRNA and protein products of the melanin‐concentrating hormone (MCH) receptor gene, slc‐1, in the central nervous system of the rat. Eur J Neurosci 2000;12:1194–1216. [DOI] [PubMed] [Google Scholar]
  • 15. Jezova D, Bartanusz V, Westergren I, et al. Rat melanin‐concentrating hormone stimulates adrenocorticotropin secretion: evidence for a site of action in brain regions protected by the blood‐brain barrier. Endocrinology 1992;130:1024–1029. [DOI] [PubMed] [Google Scholar]
  • 16. Kehne JH, Coverdale S, McCloskey TC, Hoffman DC, Cassella JV. Effects of the CRF(1) receptor antagonist, CP 154,526, in the separation‐induced vocalization anxiolytic test in rat pups. Neuropharmacology 2000;39:1357–1367. [DOI] [PubMed] [Google Scholar]
  • 17. Kennedy AR, Todd JF, Stanley SA, et al. Melanin‐concentrating hormone (MCH) suppresses thyroid stimulating hormone (TSH) release, in vivo and in vitro, via the hypothalamus and the pituitary. Endocrinology 2001;142:3265–3268. [DOI] [PubMed] [Google Scholar]
  • 18. Kennedy AR, Todd JF, Dhillo WS, et al. Effect of direct injection of melanin‐concentrating hormone into the paraventricular nucleus: Further evidence for a stimulatory role in the adrenal axis via SLC‐1. J Neuroendocrinol 2003;15:268–272. [DOI] [PubMed] [Google Scholar]
  • 19. Knigge KM, Wagner JE. Melanin‐concentrating hormone (MCH) involvement in pentylenetetrazole (PTZ)‐induced seizure in rat and guinea pig. Peptides 1997;18:1095–1097. [DOI] [PubMed] [Google Scholar]
  • 20. Ludwig DS, Tritos NA, Mastaitis JW, et al. Melanin‐concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest 2001;107:379–386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Marsh DJ, Weingarth DT, Novi DE, et al. Melanin‐concentrating hormone 1 receptor‐deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci USA 2002;99:3240–3245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Millan MJ, Brocco M, Gobert A, Dorey G, Casara P, Dekeyne A. Anxiolytic properties of the selective, non‐peptidergic CRF(1) antagonists, CP154,526 and DMP695: A comparison to other classes of anxiolytic agent. Neuropsychopharmacology 2001;25:585–600. [DOI] [PubMed] [Google Scholar]
  • 23. Monzon ME, de Souza MM, Izquierdo LA, Izquierdo I, Barros DM, de Barioglio SR. Melanin‐concentrating hormone (MCH) modifies memory retention in rats. Peptides 1999;20:1517–1519. [DOI] [PubMed] [Google Scholar]
  • 24. Njung'e K, Handley SL. Evaluation of marble‐burying behavior as a model of anxiety. Pharmacol Biochem Behav 1991;38:63–67. [DOI] [PubMed] [Google Scholar]
  • 25. Reeves DL, Levinson DM, Justesen DR, Lubin B. Endogenous hyperthermia in normal human subjects: Experimental study of emotional states (II). Int J Psychosom 1985;32:18–23. [PubMed] [Google Scholar]
  • 26. Roy M, David NK, Danao JV, Baribault H, Tian H, Giorgetti M. Genetic inactivation of melanin‐concentrating hormone receptor subtype 1 (MCHR1) in mice exerts anxiolytic‐like behavioral effects. Neuropsychopharmacology; In press. [DOI] [PubMed] [Google Scholar]
  • 27. Qu D, Ludwig DS, Gammeltoft S, et al. A role for melanin‐concentrating hormone in the central regulation of feeding behaviour. Nature 1996;380:243–247. [DOI] [PubMed] [Google Scholar]
  • 28. Saito Y, Cheng M, Leslie FM, Civelli O. Expression of the melanin‐concentrating hormone (MCH) receptor mRNA in the rat brain. J Comp Neurol 2001;435:26–40. [DOI] [PubMed] [Google Scholar]
  • 29. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos‐Flier E. Mice lacking melanin‐concentrating hormone are hypophagic and lean. Nature 1998;396:670–674. [DOI] [PubMed] [Google Scholar]
  • 30. Smith DG, Tzavara ET, Shaw J, et al. Mesolimbic dopamine super‐sensitivity in melanin‐concentrating hormone‐1 receptor‐deficient mice. J Neurosci 2005;25:914–922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Smith DG, Davis RJ, Rorick‐Kehn L, et al. Melanin‐concentrating hormone‐1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice. Neuropsychopharmacology; In press. [DOI] [PubMed] [Google Scholar]
  • 32. Verret L, Goutagny R, Fort P, et al. A role of melanin‐concentrating hormone producing neurons in the central regulation of paradoxical sleep. BMC Neurosci 2003;4:19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Wolinsky TD, Craig DA, Patel J, Lichtblau H, Papp M, Gerald CP. Anxiolytic and antidepressant‐like activity of SNAP94847, a novel MCH‐1 antagonist. Abstr 34th Soc Neurosci Meeting 2004;#356.14.

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES